La catena delle opzioni mostra i dati chiave delle opzioni azionarie di DBV Technologies a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per DBV Technologies..

DBV Technologies (NASDAQ:DBVT) Azioni, Catena delle Opzioni

DBV Technologies

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.

DBV Technologies S.A. - American Depositary Shares

DBV Technologies SA

DBV TECHNOLOGIES SA by DBV Technologies SA

News

Stock Split

DBVT

DBV Technologies Plans To Change Ratio From 1 ADS to 1 Ordinary Share To 1 ADS To 5 Ordinary Shares

WIIM

DBV Technologies shares are trading higher after HC Wainwright & Co. maintained a Buy rating on the stock and raised its price target from $5 to $7.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird raised ServiceNow, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) price target from $900 to $975. Baird analyst Rob Oliver maintained an Outperform rating. ServiceNow shares closed at $907.68 on Wednesday. <a href="https://www.benzinga.com/quote/NOW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc raised the price target for Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) from $11 to $12. Keybanc analyst Michael Leshock maintained an Overweight rating. Rocket Lab shares closed at $10.91 on Wednesday. <a href="https://www.benzinga.com/quote/RKLB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler cut the price target for Synopsys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) from $687 to $670. Piper Sandler analyst Clarke Jeffries maintained an Overweight rating. Synopsys shares closed at $493.41 on Wednesday. <a href="https://www.benzinga.com/quote/SNPS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. raised DBV Technologies S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) price target from $5 to $7. HC Wainwright &amp; Co. analyst Andrew Fein maintained a Buy rating. DBV Technologies shares settled at $0.6801 on Wednesday. <a href="https://www.benzinga.com/quote/DBVT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham boosted Teledyne Technologies Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDY#NYSE">TDY</a>) price target from $482 to $528. Needham analyst James Ricchiuti maintained a Buy rating. Teledyne Technologies shares closed at $470.09 on Wednesday. <a href="https://www.benzinga.com/quote/TDY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan cut NextEra Energy Partners, LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEP#NYSE">NEP</a>) price target from $25 to $22. JP Morgan analyst Mark Strouse upgraded the stock from Underweight to Neutral. NextEra Energy shares closed at $21.01 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/NEP/analyst-ratings">how </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">other analysts view this stock</a>.</li>
<li>BMO Capital cut the price target for CoStar Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>) from $78 to $75. BMO Capital analyst Jeffrey Silber maintained a Market Perform rating. CoStar shares settled at $72.82 on Wednesday. <a href="https://www.benzinga.com/quote/CSGP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised Amphenol Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) price target from $70 to $74. B of A Securities analyst Wamsi Mohan maintained a Neutral rating. Amphenol shares closed at $68.47 on Wednesday. <a href="https://www.benzinga.com/quote/APH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised the price target for Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) from $255 to $265. B of A Securities analyst John Murphy maintained a Buy rating. Tesla shares closed at $213.65 on Wednesday. <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stephens &amp; Co. boosted East West Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>) price target from $91 to $104. Stephens &amp; Co. analyst Andrew Terrell maintained an Overweight rating. East West Bancorp shares closed at $95.63 on Wednesday. <a href="https://www.benzinga.com/quote/EWBC/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read More:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41512422/top-3-tech-stocks-youll-regret-missing-in-q4">Top 3 Tech Stocks You&#8217;ll Regret Missing In Q4</a></li>
</ul>

Price Target

Pre-Market Outlook

Analyst Ratings

CSGP

EWBC

RKLB

SNPS

TSLA

Tesla To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Thursday

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares increased by 27.4% to $3.16 during Thursday's pre-market session. The company's market cap stands at $539.2 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares moved upwards by 24.11% to $0.17. The market value of their outstanding shares is at $5.6 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock rose 21.51% to $0.83. The market value of their outstanding shares is at $79.4 million. </li>
<li>MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) stock moved upwards by 19.65% to $2.07. The company's market cap stands at $101.5 million. </li>
<li>Qualigen Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLGN#NASDAQ">QLGN</a>) shares increased by 17.24% to $0.2. The market value of their outstanding shares is at $5.5 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock rose 14.78% to $2.95. The company's market cap stands at $23.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares declined by 16.8% to $0.11 during Thursday's pre-market session. The market value of their outstanding shares is at $10.8 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock decreased by 13.59% to $2.29. The company's market cap stands at $5.9 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock declined by 13.56% to $0.35. The market value of their outstanding shares is at $4.8 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock declined by 12.27% to $0.93. The company's market cap stands at $1.8 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares declined by 12.13% to $0.29. The market value of their outstanding shares is at $5.2 million. </li>
<li>Anitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) stock decreased by 9.18% to $0.52. The company's market cap stands at $3.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AZTR

BIVI

CNSP

CYCC

ENSC

GNPX

MNOV

NDRA

Qualigen Therapeutics, Inc. - Common Stock

QLGN

TVGN

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock rose 28.6% to $3.19 during Thursday's pre-market session. The company's market cap stands at $544.3 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares moved upwards by 24.04% to $0.17. The company's market cap stands at $5.6 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock rose 22.17% to $0.83. The company's market cap stands at $79.9 million. </li>
<li>MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) shares moved upwards by 19.65% to $2.07. The company's market cap stands at $101.5 million. </li>
<li>Qualigen Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLGN#NASDAQ">QLGN</a>) stock rose 14.82% to $0.2. The company's market cap stands at $5.3 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock moved upwards by 14.78% to $2.95. The market value of their outstanding shares is at $23.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares declined by 16.9% to $0.11 during Thursday's pre-market session. The company's market cap stands at $10.8 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares decreased by 13.97% to $2.28. The market value of their outstanding shares is at $5.9 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock fell 13.24% to $0.35. The market value of their outstanding shares is at $4.8 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock declined by 12.27% to $0.93. The market value of their outstanding shares is at $1.8 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares decreased by 12.13% to $0.29. The market value of their outstanding shares is at $5.2 million. </li>
<li>Anitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) stock decreased by 9.18% to $0.52. The company's market cap stands at $3.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Shares of Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose sharply in today's pre-market trading after the company reported stronger-than-expected <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41509528/tesla-bull-gary-black-praises-ev-giants-clean-beat-in-q3-as-auto-margins-blow-past-">earnings for its third quarter</a>.
The automaker reported third-quarter earnings per share of 72 cents, beating a Street consensus estimate of 58 cents per share.
Tesla shares jumped 10.8% to $236.82 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>CCSC Technology International Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCTG#NASDAQ">CCTG</a>) rose 122% to $3.8800 in pre-market trading after gaining around 4% on Wednesday.</li>
<li>Mobile-health Network Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) gained 46.1% to $0.7449 in pre-market trading as the company posted FY24 results.</li>
<li>Qualigen Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLGN#NASDAQ">QLGN</a>) shares rose 37.4% to $0.2390 in pre-market trading.</li>
<li>CNS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares surged 36.2% to $0.1920 in pre-market trading after declining around 10% on Wednesday. CNS Pharmaceuticals announced the pricing of $3 million registered direct offering of common stock priced at-the-market under Nasdaq rules.</li>
<li>Twin Vee Powercats Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) rose 35.9% to $0.5874 in pre-market trading after gaining 16% on Wednesday.</li>
<li>DBV Technologies S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares jumped 21% to $0.8226 in pre-market trading. HC Wainwright &amp; Co. analyst Andrew Fein maintained DBV Technologies with a Buy rating and raised the price target from $5 to $7.</li>
<li>Seadrill Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDRL#NYSE">SDRL</a>) shares rose 13.1% to $39.78 in pre-market trading. Seadrill will report its third quarter results on Tuesday, Nov. 12 after the closing bell.</li>
<li>Inhibikase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) climbed 11.1% to $2.70 in pre-market trading after jumping 15% on Wednesday.</li>
<li>Garrett Motion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTX#NASDAQ">GTX</a>) gained 8.3% to $8.65 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>SaverOne 2014 Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) shares dipped 25.9% to $0.1079 in pre-market trading after surging 12% on Wednesday.</li>
<li>Gold Resource Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GORO#NYSE">GORO</a>) shares fell 25.8% to $0.3670 in pre-market trading after the company reported preliminary third-quarter and year-to-date results.</li>
<li>Osisko Development Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ODV#NYSE">ODV</a>) fell 18.6% to $2.05 in today's pre-market trading. Osisko Development announced a $50 million marketed private placement of 27,778,000 unit at $1.80/unit.</li>
<li>Zapata Computing Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZPTA#NASDAQ">ZPTA</a>) fell 17.2% to $0.0750 in pre-market trading after jumping 43% on Wednesday.</li>
<li>KWESST Micro Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWE#NASDAQ">KWE</a>) fell 16.3% to $2.09 in pre-market trading after jumping 112% on Wednesday.</li>
<li>Orangekloud Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKT#NASDAQ">ORKT</a>) shares fell 15.1% to $6.46 in pre-market trading.</li>
<li>ICON Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) declined 16.3% to $235.13 in pre-market trading following worse-than-expected third-quarter financial results.</li>
<li>La Rosa Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRHC#NASDAQ">LRHC</a>) shares declined 15.9% to $0.9501 in pre-market trading after gaining over 130% on Wednesday. La Rosa Holdings reported preliminary 9-month revenue growth of 120% year over year.</li>
<li>Carrier Global Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) shares declined 9.9% to $72.00 in pre-market trading following worse-than-expected third-quarter revenues.</li>
<li>International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) shares fell 5% to $221.28 following a third-quarter revenue miss.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41508985/dow-records-worst-session-in-over-a-month-apple-nvidia-drag-nasdaq-down-fear-index-remains-in-greed">Dow Records Worst Session In Over A Month, Apple, Nvidia Drag Nasdaq Down: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Markets

Trading Ideas

CARR

CCTG

GORO

ICLR

LRHC

MNDR

ORKT

SDRL

SVRE

VEEE

ZPTA

Why Tesla Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket

HC Wainwright &amp; Co. analyst Andrew Fein maintains DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) with a Buy and raises the price target from $5 to $7.

HC Wainwright & Co. Maintains Buy on DBV Technologies, Raises Price Target to $7

<h3>Gainers</h3>
<ul>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock rose 16.2% to $0.16 during Wednesday's after-market session. The market value of their outstanding shares is at $5.2 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock rose 9.85% to $0.75. The market value of their outstanding shares is at $71.8 million. </li>
<li>Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) stock rose 9.45% to $301.0. The company's market cap stands at $17.6 billion. As per the press release, Q3 earnings came out today. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock increased by 8.94% to $2.8. The market value of their outstanding shares is at $22.3 million. </li>
<li>Allakos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLK#NASDAQ">ALLK</a>) shares increased by 7.63% to $1.15. The market value of their outstanding shares is at $102.1 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock increased by 7.36% to $0.36. The company's market cap stands at $3.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) shares decreased by 10.9% to $0.49 during Wednesday's after-market session. The market value of their outstanding shares is at $4.3 million. </li>
<li>Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) stock decreased by 8.17% to $3.26. The market value of their outstanding shares is at $1.1 billion. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) shares declined by 6.9% to $1.35. The market value of their outstanding shares is at $18.2 million. </li>
<li>Community Health Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) shares declined by 6.67% to $5.18. The market value of their outstanding shares is at $719.7 million. As per the news, the Q3 earnings report came out today. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) stock decreased by 6.48% to $0.28. The market value of their outstanding shares is at $10.5 million. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) stock fell 6.39% to $0.3. The company's market cap stands at $22.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLK

BIAF

ENVB

INAB

MBIO

PTPI

12 Health Care Stocks Moving In Wednesday's After-Market Session

On Tuesday, DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) announced progress in its regulatory efforts for the Viaskin Peanut patch, aimed at treating peanut allergies in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41467627/dbv-announces-positive-regulatory-updates-for-the-viaskin-peanut-patch-in-the-united-states-and-eu" rel="noreferrer noopener">toddlers and children</a>.
The company has aligned with the FDA under the Accelerated Approval Program for toddlers aged 1–3.
DBV has agreed to the FDA&#8217;s guidance on key study components required for approval, including the COMFORT Toddlers safety study, which must be completed before the US marketing application submission, and a confirmatory study to demonstrate the patch&#8217;s effectiveness.
DBV plans to begin enrolling subjects in the COMFORT Toddlers study in the second quarter of 2025, with <a target="_blank" href="https://www.benzinga.com/general/biotech/23/08/33487292/dbv-technologies-advances-peanut-allergy-program-with-fda-support-on-pediatric-studies" rel="noreferrer noopener">around 300–350 toddlers</a>.
DBV has also made headway on the Viaskin Peanut patch for older children. In September 2024, the company completed patient screening for the Phase 3 VITESSE trial, enrolling 654 children aged 4–7 years. Topline data are expected in the fourth quarter of 2025.
Discussions between DBV and the FDA have also addressed the patch&#8217;s adhesion issues. The company proposed a labeling solution that links adhesion data to the patch&#8217;s efficacy and safety.
DBV also received scientific advice from the European Medicines Agency for a broader age range of 1–7 years in Europe.
In Europe, DBV has received scientific advice confirming that the EPITOPE study in 1–3-year-olds and positive results from the VITESSE study could support the European marketing application for the 1–7-year-old age group.
The company is planning a new safety study for toddlers with the modified patch to meet European requirements.
Despite its clinical progress, DBV&#8217;s financial situation raises concerns. The company reported cash and cash equivalents of $46.4 million as of September 30, 2024, and anticipates that this will fund operations only through the first quarter of 2025.
With ongoing operating losses, DBV has expressed uncertainty about its ability to continue operations without securing additional funding. The company is actively seeking new capital to support its research and potential product launch.
Price Action: DBVT stock is up 44.3% at $1.02 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41486950/boeing-q3-earnings-revenue-and-profit-decline-cultural-challenges-ceo-ortberg-vows-transformation" target="_blank" rel="noreferrer noopener">Boeing Q3 Earnings: Revenue And Profit Decline, Cultural Challenges, CEO Ortberg Vows Transformation</a>.</li>
</ul>

Health Care

General

Penny Stock DBV Technologies Advances Viaskin Peanut Allergy Patch With FDA Approval Pathway

<h3>Gainers</h3>
<ul>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares rose 92.5% to $0.3 during Wednesday's regular session. The company's market cap stands at $9.6 million. </li>
<li>Virax Biolabs Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) stock rose 63.89% to $2.75. The market value of their outstanding shares is at $11.9 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock moved upwards by 59.31% to $2.56. The company's market cap stands at $437.7 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock rose 42.54% to $1.0. The company's market cap stands at $95.9 million. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares increased by 36.35% to $1.65. The company's market cap stands at $343.5 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock increased by 22.47% to $4.12. The market value of their outstanding shares is at $32.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Alto Neuroscience (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>) shares declined by 66.1% to $4.93 during Wednesday's regular session. The market value of their outstanding shares is at $132.9 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock fell 27.74% to $0.33. The market value of their outstanding shares is at $4.4 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares decreased by 26.44% to $0.4. The company's market cap stands at $5.4 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares fell 25.26% to $0.72. The market value of their outstanding shares is at $2.1 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock fell 25.18% to $1.07. The company's market cap stands at $2.1 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock fell 23.73% to $1.8. The market value of their outstanding shares is at $3.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANRO

ALPS ETF Trusthen & Steers Global Realty Majors ETF

NUWE

SGMO

SLXN

VRAX

12 Health Care Stocks Moving In Wednesday's Intraday Session

DBV Technologies shares are trading higher after the company announced regulatory updates for the Viaskin Peanut patch in the United States and Europe.

<h3>Gainers</h3>
<ul>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock moved upwards by 143.7% to $0.38 during Wednesday's pre-market session. The market value of their outstanding shares is at $12.2 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock increased by 62.87% to $1.14. The market value of their outstanding shares is at $109.6 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares increased by 46.15% to $2.09. The company's market cap stands at $4.1 million. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares moved upwards by 34.59% to $0.38. The market value of their outstanding shares is at $14.1 million. </li>
<li>LakeShore Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSB#NASDAQ">LSB</a>) shares moved upwards by 25.49% to $3.2. The market value of their outstanding shares is at $61.0 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) shares increased by 19.34% to $4.01. The company's market cap stands at $32.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Alto Neuroscience (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>) stock decreased by 62.3% to $5.48 during Wednesday's pre-market session. The company's market cap stands at $147.7 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares declined by 18.58% to $0.44. The market value of their outstanding shares is at $6.0 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock declined by 14.49% to $3.07. The company's market cap stands at $7.9 million. </li>
<li>TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) stock decreased by 14.46% to $2.13. The company's market cap stands at $52.6 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock fell 12.7% to $0.31. The market value of their outstanding shares is at $4.1 million. </li>
<li>Creative Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) stock decreased by 11.51% to $4.0. The company's market cap stands at $5.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APVO

CELZ

TELA

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares rose 143.7% to $0.38 during Wednesday's pre-market session. The company's market cap stands at $12.2 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock moved upwards by 62.87% to $1.14. The company's market cap stands at $109.6 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock moved upwards by 46.15% to $2.09. The market value of their outstanding shares is at $4.1 million. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares rose 34.59% to $0.38. The company's market cap stands at $14.1 million. </li>
<li>LakeShore Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSB#NASDAQ">LSB</a>) stock rose 25.49% to $3.2. The market value of their outstanding shares is at $61.0 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock increased by 19.34% to $4.01. The market value of their outstanding shares is at $32.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Alto Neuroscience (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>) shares decreased by 62.3% to $5.48 during Wednesday's pre-market session. The market value of their outstanding shares is at $147.7 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares decreased by 18.58% to $0.44. The company's market cap stands at $6.0 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock decreased by 14.49% to $3.07. The company's market cap stands at $7.9 million. </li>
<li>TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) shares fell 14.46% to $2.13. The company's market cap stands at $52.6 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock declined by 12.7% to $0.31. The company's market cap stands at $4.1 million. </li>
<li>Creative Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) stock declined by 11.51% to $4.0. The market value of their outstanding shares is at $5.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Shares of Stride, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRN#NYSE">LRN</a>) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results and issued FY25 revenue <a href="https://www.benzinga.com/quote/LRN">guidance above estimates</a>.
Stride reported quarterly earnings of 94 cents per share which beat the analyst consensus estimate of 20 cents per share. The company reported quarterly sales of $551.084 million which beat the analyst consensus estimate of $506.081 million.
Stride shares jumped 24.3% to $80.25 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>CNS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) rose 99.4% to $0.3124 in pre-market trading after jumping around 7% on Tuesday.</li>
<li>DBV Technologies S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) gained 75.7% to $1.23 in pre-market trading as the company announced positive regulatory updates for the Viaskin&#xAE; Peanut Patch in the United States and Europe.</li>
<li>Mustang Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares surged 60.6% to $0.4531 in pre-market trading after declining around 4% on Tuesday.</li>
<li>Farmmi, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAMI#NASDAQ">FAMI</a>) rose 55.2% to $0.4890 in pre-market trading after gaining 4% on Tuesday.</li>
<li>Zapata Computing Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZPTA#NASDAQ">ZPTA</a>) shares rose 39.6% to $0.0885 in pre-market trading after dipping around 18% on Tuesday.</li>
<li>ShiftPixy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIXY#NASDAQ">PIXY</a>) shares jumped 30.3% to $10.67 in pre-market trading. ShiftPixy signed a LOI to acquire AI innovator TurboScale in a $150 million deal.</li>
<li>Phunware, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) climbed 23.4% to $14.37 in pre-market trading after jumping 38% on Tuesday.</li>
<li>22nd Century Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) gained 19.3% to $0.1387 in pre-market trading after gaining over 10% on Tuesday.</li>
<li>Daqo New Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DQ#NYSE">DQ</a>) shares rose 15.8% to $24.10 in pre-market trading. Daqo New Energy will release its unaudited financial results for the third quarter before the opening bell on Wednesday, Oct. 30.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Alto Neuroscience, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>) shares dipped 61.4% to $5.59 in pre-market trading after the company announced topline results from a Phase 2b trial evaluating ALTO-100 as a treatment for major depressed disorder did not meet its primary endpoint.</li>
<li>Genprex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares fell 20.9% to $2.84 in pre-market trading after jumping around 138% on Tuesday.</li>
<li>Ensysce Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) fell 19.3% to $0.4351 in pre-market trading after jumping 162% on Tuesday.</li>
<li>Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) fell 18.8% to $0.2973 in today's pre-market trading after jumping around 50% on Tuesday.</li>
<li>Neo-Concept International Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCI#NASDAQ">NCI</a>) fell 18.2% to $0.7233 in pre-market trading after dipping 37% on Tuesday.</li>
<li>Chanson International Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHSN#NASDAQ">CHSN</a>) shares fell 17.2% to $9.92 in pre-market trading.</li>
<li>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) declined 15.2% to $78.21 in pre-market trading after the company reported worse-than-expected third-quarter financial results.</li>
<li>Aptevo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares declined 14.3% to $0.3023 in pre-market trading after gaining over 48% on Tuesday.</li>
<li>XBP Europe Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBP#NASDAQ">XBP</a>) shares declined 11.9% to $1.18 in pre-market trading.</li>
<li>McDonald&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) shares fell 7.2% to $292.20 following CDC reports of an E. coli outbreak linked to quarter pounders.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41479244/dow-edges-lower-as-investors-watch-earnings-reports-with-caution-fear-index-remains-in-greed-zone">Dow Edges Lower As Investors Watch Earnings Reports With Caution: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

CHSN

DBGI

ENPH

FAMI

PHUN

PIXY

XXII

Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket

DBV Announces Positive Regulatory Updates for the Viaskin&#xAE; Peanut Patch in the United States and Europe
<ul>
<li>DBV to pursue an Accelerated Approval pathway for toddlers ages 1 – 3 years-old&nbsp;</li>
<li>BLA submission under Accelerated Approval is subject to completion of a six-month supplemental safety study in toddlers to be initiated in Q2 2025</li>
<li>VITESSE Phase 3 study evaluating the Viaskin Peanut patch in children ages 4 – 7 years-old exceeded enrollment goals; Topline results on track for 4Q 2025&nbsp;&nbsp;</li>
<li>European Medicines Agency (EMA) scientific advice confirms registration path for a Marketing Authorization Application (MAA) with the modified Viaskin peanut patch for a 1 – 7 year-old indication in Europe</li>
<li>Company to host investor conference call at 5:00pm ET today &nbsp;</li>
</ul>
DBV Technologies (TRQX:<a href="https://www.benzinga.com/stock/DBVp#TRQX">DBVp</a>), a clinical-stage biopharmaceutical company, today announced positive regulatory updates for the Viaskin Peanut patch in the United States and Europe. DBV has agreed to guidance provided by the U.S. Food and Drug Administration (FDA) on a pathway under the Accelerated Approval Program for the Viaskin Peanut patch in toddlers ages 1 – 3 years-old and has also received scientific advice from the EMA on a 1 – 7 year-old indication in Europe. DBV intends to formalize the Accelerated Approval guidance provided by the FDA via submission of a meeting request.

Biotech

Global

DBV Announces Regulatory Updates For The Viaskin Peanut Patch In The U.S. And Europe; BLA Submission Under Accelerated Approval Is Subject To Completion Of A 6-Month Supplemental Safety Study In Toddlers To Be Initiated In Q2 2025; VITESSE Phase 3 Study Evaluating The Viaskin Peanut Patch In Children Ages 4 – 7 Years-old Exceeded Enrollment Goals

JMP Securities analyst Jonathan Wolleben reiterates DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) with a Market Outperform and maintains $5 price target.

Reiteration

JMP Securities Reiterates Market Outperform on DBV Technologies, Maintains $5 Price Target

DBV Technologies Completes Screening For VITESSE Phase 3 Trial Evaluating Viaskin Peanut Patch In Children Ages 4-7; Topline Results Expected By Q4 2025

HC Wainwright &amp; Co. analyst Andrew Fein reiterates DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) with a Buy and maintains $5 price target.

HC Wainwright & Co. Reiterates Buy on DBV Technologies, Maintains $5 Price Target

JMP Securities analyst Jonathan Wolleben maintains DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) with a Market Outperform and raises the price target from $4 to $5.

JMP Securities Maintains Market Outperform on DBV Technologies, Raises Price Target to $5

The Company intends to seek additional capital as it continues research and development efforts and prepares for the launch of Viaskin Peanut, if approved. The Company cannot guarantee that it will be able to obtain the necessary financing to meet its needs or to obtain funds at attractive terms and conditions, including as a result of disruptions to the global financial markets due to any future pandemics, epidemics or global health crises and conflict in Ukraine or other global political or military crises. A severe or prolonged economic downturn could result in a variety of risks to the Company, including reduced ability to raise additional capital when needed or on acceptable terms, if at all.
If the Company is not successful in its financing objectives, the Company could have to scale back its operations, notably by delaying or reducing the scope of its research and development efforts or obtain financing through arrangements with collaborators or others that may require the Company to relinquish rights to its product candidates that the Company might otherwise seek to develop or commercialize independently.
This interim condensed financial information does not include any adjustments to the carrying amounts and classification of assets, liabilities, and reported expenses that may be necessary if the Company was unable to continue as a going concern.

DBV Technologies Faces Uncertainties In Securing Necessary Financing Under Favorable Terms Due To Potential Global Financial Disruptions, With Risks Exacerbated By Economic Downturns, Potentially Forcing Operational Scale-Backs Or Unwanted Collaborative Financial Arrangements, Without Adjustments Made In This Financial Statement For Going Concern Uncertainties

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Goldman Sachs analyst Rajan Sharma notes that DBV Technologies (DBVT) stated In its most recent press release that there is substantial doubt regar...

DBV Technologies rating suspended at Goldman Sachs

Warning: DBVT is at high risk of performing badly

DBV Technologies GAAP EPS of -$0.32 beats by $0.03

Kepler Capital analyst Justine Telliez maintained a Buy rating on DBV Technologies (0QAJ – Research Report) on November 7 and set a price target of...

Kepler Capital  Sticks to Its Buy Rating for DBV Technologies (0QAJ)

DBV Technologies to implement ADS ratio change

DBV Technologies (DBVT) announced plans to change the ratio of its American Depositary Shares, or ADSs, to its ordinary shares, nominal value EUR 0...

DBV Technologies announces ADS ratio change

An update from DBV Technologies SA – American ( ($DBVT) ) is now available. DBV Technologies has announced a significant change in the ratio of its...

DBV Technologies Adjusts ADS Ratio to Meet Nasdaq Rules

In a report released on November 12, Justine Telliez from Kepler Capital maintained a Buy rating on DBV Technologies (0QAJ – Research Report), with...

DBV Technologies (0QAJ) Receives a Buy from Kepler Capital

Option delistings effective November 18th include BioCardia (BCDA), DBV Technologies (DBVT), ACN 650 026 314 Ltd (DCFCQ), DouYu International (DOYU...

Comments

DBV Technologies

DBV Technologies (DBVT) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO